Methods:

Organ retrieval Nutlin-3a and cold perfusion were performed in a standardized fashion using University of Wisconsin solution. In addition, blood from the donor was collected as perfusion solution. The perfusion circuit consisted of a single centrifugal pump which circulates perfusate out of the inferior vena cava through an oxygenator / heat exchanger and then split into a pressure-controlled hepatic artery supply and gravity fed portal venous supply via a reservoir. Throughout the perfusion period of up to six hours there was continuous monitoring of haemo-dynamic parameters and blood, bile, liver and bile duct tissue samples were collected. Results: At the time of submission, one liver donated after cardiac death (DCD) and one donated after brain

death (DBD) have been studied. Both livers were meta-bolically active throughout the perfusion period reflected by lactate clearance (peak lactate 9 and 8.16 mmol/L; 0.95 and 2.56 mmol/L at the end of perfusion), urea production (4.4 and 4 mmol/L at start of perfusion; 11 and 7.9 mmol/L at end of perfusion) and bile production. Liver histology obtained at the end of the perfusion period showed no evidence of hepatocellular injury. However, there was extensive biliary injury in the DCD liver as reflected by epithelial cell loss and mural necrosis of both the left and right hepatic duct. Conclusion: This study shows that normothermic oxygenated machine perfusion is feasible from a technical perspective Anti-infection Compound Library concentration Sinomenine in donor liver currently deemed unsuitable for transplant. This continuing study is comparing the results of both DCD and DBD donor livers. The extensive degree of biliary damage in the DCD liver may underline the need to consider biliary tract integrity when assessing graft viability.

Disclosures: Darrell H. Crawford – Advisory Committees or Review Panels: Roche Products Pty Ltd, Bristol Myers Squibb, Gilead Sciences, Novartis, MSD, Abbvie, Jansen; Consulting: Roche Products Pty Ltd; Grant/Research Support: Roche Products Pty Ltd; Speaking and Teaching: Roche Products Pty Ltd, Bristol Myers Squibb, Gilead Sciences, MSD The following people have nothing to disclose: Janske Reiling, David S. Lockwood, Andrew H. Simpson, Catherine M. Campbell, Kim Bridle, Nishreen Santrampurwala, Laurence J. Britton, Cornelis H. Dejong, Jonathan Fawcett Background and Aims: Zinc is an important trace element with catalytic and defensive functions. We assessed the impact of zinc deficiency in patients with end-stage liver disease (ESLD) awaiting liver transplantation. Methods: Serum zinc levels were measured at the time of evaluation for liver transplantation in ESLD patients (n = 265). Patients were dichotomized in two groups: low and normal zinc serum levels. Results: Medium serum zinc levels were 8.59 μmol/l ± 3.1.